EyePoint Pharmaceuticals, Inc.

NASDAQ:EYPT

Biotechnology

Healthcare
$2.99 +1.98%

+$0.26 today

Market cap
$250.69M
Beta
1.75
P/E (TTM)
-4.2
EPS (TTM)
-$3.16
52W Low $7.94High $19.11

Volume 2.75M

Average 0.95M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$240.11M

FY 2025 · Annual

Investing Cash Flow

$68.58M

FY 2025 · Annual

Financing Cash Flow

$173.65M

FY 2025 · Annual

+5.9% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(58.42M)(102.25M)(70.8M)(130.87M)(231.96M)
Depreciation & Amortization2.77M2.45M464K1.54M2.31M
Deferred Income Tax(787K)083K90K279K
Stock-Based Compensation7.45M14.18M12.06M36.74M27.87M
Change in Working Capital(1.74M)(3.02M)58.88M(27.77M)(33.78M)
Accounts Receivables(10.6M)(2.66M)14.43M(244K)(10.67M)
Inventory1.35M(760K)(1.55M)1.6M492K
Accounts Payables8.48M1.2M1.52M5.73M4.68M
Other Working Capital(959K)(799K)44.48M(34.86M)(28.28M)
Other Non-Cash Items628K23.65M1.18M(5.95M)(4.83M)
Operating Cash Flow(50.1M)(65.01M)1.88M(126.23M)(240.11M)
Capital Expenditures(156K)(2.15M)(3.48M)(4.05M)(3.28M)
Acquisitions (Net)0(558K)(168K)0155K
Purchases of Investments(32.97M)(139.12M)(55.12M)(398.3M)(252.02M)
Sales of Investments0124M55.28M177.05M318.9M
Other Investing Activities0558K168K5.95M4.83M
Investing Cash Flow(33.12M)(17.27M)(3.32M)(219.36M)68.58M
Debt Repayment(146K)2.1M(40.51M)(105K)(105K)
Common Stock Issued216.83M395K226.17M163.31M175.14M
Common Stock Repurchased0(295K)000
Dividends Paid00000
Other Financing Activities223K(3.19M)1.41M813K(1.39M)
Financing Cash Flow216.9M(690K)187.07M164.02M173.65M
Effect of Forex Changes00000
Net Change in Cash133.68M(82.96M)185.63M(181.56M)2.12M
Free Cash Flow(50.25M)(67.16M)(1.61M)(130.28M)(243.39M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$232.0M
+ D&A$2.3M
+ Stock-Based Comp$27.9M
+ Deferred Tax$279.0K
- Working Capital-$33.8M
- Other Non-Cash-$4.8M
= Operating Cash Flow-$240.1M
- Capex-$3.3M
= Free Cash Flow-$243.4M

Analysis

FY2025 free cash flow is -$243.4M. FCF conversion is 104.9% of net income. Operating cash flow was -$240.1M, with capex of -$3.3M. The largest bridge item is Working Capital at -$33.8M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingOct 7, 2026
8-KCurrent reportSep 10, 2026
SC 13GSC 13G filingSep 8, 2026
4Statement of changes in beneficial ownershipAug 24, 2026
4Statement of changes in beneficial ownershipAug 18, 2026

Does EYPT generate free cash flow?

EyePoint Pharmaceuticals, Inc. (EYPT) generated -$243.39M of free cash flow in fiscal 2025.

How much operating cash flow does EYPT produce?

Operating cash flow was -$240.11M, before capital expenditures of $3.28M.